Inovio Pharmaceuticals, Inc. — FY2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016. The filing was signed March 15, 2017. Inovio is a clinical-stage biotechnology company developing DNA immunotherapies and vaccines with electroporation delivery; it reported no product sales and no approved human products.
Financial performance and position
| Metric | FY2016 | FY2015 |
|---|---|---|
| Revenue | $35.4 million | $40.6 million |
| Operating expenses | $111.6 million | $74.9 million |
| Research and development | $88.7 million | $57.8 million |
| General and administrative | $23.9 million | $18.1 million |
| Loss from operations | $76.2 million | $34.3 million |
| Net loss attributable to Inovio | $73.7 million | $29.2 million |
| Basic loss per share | $1.01 | $0.43 |
| Cash used in operating activities | $62.6 million | $12.4 million |
- Revenue fell 13%; collaborative R&D revenue dropped $19.8 million, partly offset by a $14.6 million increase in grants and miscellaneous revenue. DARPA accounted for 75% of FY2016 revenue, compared with 28% in FY2015.
- Operating expenses rose 49%, primarily as R&D spending increased to support clinical programs, staffing, the DARPA Ebola work and VGX-3100 Phase 3 preparation. Stock-based compensation was $10.2 million.
- At year-end, cash and cash equivalents were $19.1 million and short-term investments were $85.6 million, totaling $104.8 million. Working capital was $80.8 million; current assets were $124.6 million and current liabilities $43.8 million.
- Total liabilities were $50.3 million, including $6.4 million of noncurrent deferred rent. The company reported no material long-term debt or other material long-term contractual obligations apart from operating leases. Lease commitments totaled $26.1 million.
- Year-end total assets were $173.7 million, stockholders’ equity was $123.4 million, and accumulated deficit was $434.8 million. The 2016 operating cash outflow was partly offset by $7.8 million of financing cash, including $6.3 million net proceeds from ATM share sales.
- For Q4 2016, revenue was $8.5 million and net loss attributable to Inovio was $26.2 million, or $0.35 per basic share.
Material changes and notable developments
- Net loss widened to $73.7 million from $29.2 million, while operating cash use increased to $62.6 million from $12.4 million. Revenue also became more concentrated in government funding, especially DARPA.
- The FDA placed the proposed VGX-3100 Phase 3 program on a device-focused clinical hold in October 2016, requesting additional information, including stability data for the CELLECTRA 5PSP disposable electrode array. The trial had not begun; the filing states the hold was not related to a safety issue in an ongoing study. Management aimed to start the trial in the first half of 2017.
- Roche discontinued development of INO-1800 for hepatitis B; the rights returned to Inovio. The company planned to continue the Phase 1 study independently. Roche paid $8.5 million in February 2017 for past and future termination-related obligations.
- In April 2016, Inovio acquired Bioject’s needle-free injection technology and related assets for $5.5 million, comprising $4.3 million in stock and $1.2 million in cash.
- The filing reports an unqualified audit opinion on the financial statements and an unqualified opinion that internal control over financial reporting was effective at December 31, 2016.
Outlook, risks and contingencies
- Management expected substantial operating losses to continue for years and stated that year-end cash and short-term investments were sufficient for planned working-capital needs for at least 12 months. The company also said it expects to rely on external financing and may never achieve positive cash flow or profitability.
- Key development focus included advancing VGX-3100 toward Phase 3 and continuing clinical programs across cancer and infectious-disease candidates. The filing gives no quantified financial guidance for future revenue, earnings or cash burn.
- After year-end, Inovio announced an ApolloBio agreement for VGX-3100 in Greater China, subject to approvals and other conditions. It provides for $3 million at signing and a $12 million payment upon lifting of the FDA hold, plus up to $20 million in regulatory milestones and double-digit royalties. A separate proposed equity investment was capped at $35 million and was also conditional.
- Major risks include clinical and regulatory failure or delay, the unresolved VGX-3100 hold, dependence on third-party collaborators and government awards, revenue concentration, need for additional capital and potential shareholder dilution, manufacturing and supply dependence, competition, and intellectual-property risks.
- Revenue recognition and timing depend on collaboration deliverables, grant-funded work and milestones. At year-end, $12.1 million of accounts receivable was attributed to DARPA; $6.8 million was unbilled pending a subcontractor invoice. Management expected collection within 12 months.
Important facts for investors to verify
- Whether the FDA hold was lifted, what device information was required, and whether VGX-3100 Phase 3 began on the stated timeline.
- Actual cash burn, financing needs and any subsequent ATM or other equity issuance; assess dilution against the stated liquidity runway.
- Whether DARPA funding and other major collaboration revenues continued, and how customer concentration changed.
- Collection of DARPA receivables and realization of conditional ApolloBio payments, approvals and investment.
- Clinical-trial outcomes and safety data, particularly whether earlier-stage findings translate into later-stage efficacy and eventual regulatory approval.